Trade AKTS anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Aktis Oncology, Inc. (AKTS) is trading at US$27.05, up 1.50% today as of Sep 4, 16:00 EDT. The company has a market capitalisation of US$1.34B. Over the past 52 weeks, AKTS has traded between US$14.72 and US$34.19. On Syfe you can trade AKTS with $0 commission and add it to your watchlist.
| Previous close | US$26.65 |
|---|---|
| Market cap | US$1.34B |
| 52-week range | US$14.72 – US$34.19 |
| Volume | 159.25K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Aktis Oncology, Inc.
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.
Year: 2026
Aktis Oncology Insider Sold Shares Worth $1,387,558, According to a Recent SEC Filing
Jul 10, 10:27 AM · MT Newswires
Aktis Oncology, Inc. (AKTS) stock is trading at US$27.05, +1.50% from the previous close of US$26.65.
The market cap for Aktis Oncology, Inc. (AKTS) stock is approximately US$1.34B.
The 52-week high for Aktis Oncology, Inc. (AKTS) stock is US$34.19.
The 52-week low for Aktis Oncology, Inc. (AKTS) stock is US$14.72.
Aktis Oncology, Inc. (AKTS) does not currently pay a dividend.
Stay on top of AKTS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
